Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: Results from a single-arm, phase II study

Journal of Clinical Oncology

Volumn 35, Issue 14, 2017, Pages 1542-1549

  Bauml, Joshua ^a   Seiwert, Tanguy Y ^b   Pfister, David G ^c   Worden, Francis ^d   Liu, Stephen V ^f   Gilbert, Jill ^g   Saba, Nabil F ^h   Weiss, Jared ⁱ   Wirth, Lori ^j   Sukari, Ammar ^e   Kang, Hyunseok ^l   Gibson, Michael K ^m   Massarelli, Erminia ⁿ   Powell, Steven ^o   Meister, Amy ^p   Shu, Xinxin ^p   Cheng, Jonathan D ^p   Haddad, Robert ^k  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^o SANFORD RESEARCH   (United States)

^p MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; CETUXIMAB; PEMBROLIZUMAB; PLATINUM; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PLATINUM DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTHYROIDISM; HYPONATREMIA; HYPOTHYROIDISM; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERSONAL EXPERIENCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; WART VIRUS; WEIGHT REDUCTION; CARCINOMA, SQUAMOUS CELL; CHEMISTRY; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; DISEASE FREE SURVIVAL; HEAD AND NECK NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTION; PATHOLOGY; RETREATMENT; SECONDARY; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PAPILLOMAVIRUS INFECTIONS; PLATINUM COMPOUNDS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETREATMENT; SURVIVAL RATE;

EID: 85019091025     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.1524     Document Type: Article

References (23)

1. Seiwert TY, Salama JK, Vokes EE: The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 4:156-171, 2007
2. Price KA, Cohen EE: Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 13:35-46, 2012
3. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
4. Echarri MJ, Lopez-Martin A, Hitt R: Targeted therapy in locally advanced and recurrent/metastatic head and neck squamous cell carcinoma (LA-R/M HNSCC). Cancers (Basel) 8:E27, 2016
5. Machiels JP, Haddad RI, Fayette J, et al: Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): An open-label, randomised phase 3 trial. Lancet Oncol 16:583-594, 2015
6. Herbst RS, Baas P, Kim DW, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387:1540-1550, 2016
7. Seiwert TY, Burtness B, Mehra R, et al: Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol 17:956-965, 2016
8. Rizvi NA, Mazières J, Planchard D, et al: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 16:257-265, 2015
9. Muro K, Chung HC, Shankaran V, et al: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol 17:717-726, 2016
10. Strome SE, Dong H, Tamura H, et al: B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 63:6501-6505, 2003
11. Lyford-Pike S, Peng S, Young GD, et al: Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 73:1733-1741, 2013
12. Yearley J, Gibson G, Yu N, et al: 18LBA PD-L2 expression in human tumors: Relevance to anti-PD-1 therapy in cancer. Eur J Biochem 51:S718, 2016 (abstr)
13. Iwai Y, Ishida M, Tanaka Y, et al: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293-12297, 2002
14. Sui X, Ma J, Han W, et al: The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget 6:19393-19404, 2015
15. Hamid O, Robert C, Daud A, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-144, 2013
16. Robert C, Ribas A, Wolchok JD, et al: Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109-1117, 2014
17. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018-2028, 2015
18. Nanda R, Chow LQ, Dees EC, et al: Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol 34:2460-2467, 2016
19. Chow LQM, Haddad R, Gupta S, et al: Antitumor activity of pembrolizuamb in biomarker-unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: Results from the phase 1b KEYNOTE-012 expansion cohort. J Clin Oncol 34:3838-3845, 2016
20. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
21. Dako: Dako, an Agilent technologies company, announces FDA approval of new companion diagnostic for lung cancer. http://www.agilent.com/about/newsroom/presrel/2016/24oct-ca16033.html
22. Seiwert TY, Fayette J, Cupissol D, et al: A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 25:1813-1820, 2014
23. Ferris RL, Blumenschein G Jr, Fayette J, et al: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856-1867; 2016